PD-L1 Antikörper (Biotin)

Produktnummer ABIN7608341

Der Human Chimeric Anti-PD-L1-Antikörper wurde für WB validiert. Er ist geeignet, PD-L1 in Proben von Human zu detektieren.

Kurzübersicht für PD-L1 Antikörper (Biotin) (ABIN7608341)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Human

Wirt: Human, Kaninchen

Klonalität: Chimeric

Konjugat: Dieser PD-L1 Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB)

Klon: 23D8

Produktdetails anti-PD-L1 Antikörper (Biotin)

Verwendungszweck: Biotinylated Anti-PDL1 antibody(23D8), IgG1 Chimeric mAb

Aufreinigung: Purified from cell culture supernatant by affinity chromatography

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: WB 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Haltbarkeit: 12 months

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: PDL1

Hintergrund: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints